AI Article Synopsis
- This study aimed to explore the effectiveness of doxycycline when used with antifungal treatments against Mucorales pathogens, which cause mucormycosis.
- Researchers conducted tests on 21 isolates from 8 Mucorales species to see how well doxycycline worked in combination with antifungals like itraconazole, posaconazole, and amphotericin.
- Results indicated that doxycycline showed beneficial effects in combination therapies, particularly with one strain of Rhizopus arrhizus, suggesting it could enhance antifungal treatment outcomes.
Article Abstract
Purpose: Since systematic antifungals for mucormycosis showed variable MICs depending on strains, effective and safe antifungal therapy was still needed. This study is aimed to evaluate the in vitro activity of doxycycline combined with antifungal therapy against dominant Mucorales pathogens.
Methods: Multidrug susceptibility testing was performed with doxycycline and antifungals, including itraconazole, posaconazole, and amphotericin, in 21 isolates of 8 dominant Mucorales pathogens.
Results: The fractional inhibitory concentration index according to M38 showed one Rhizopus arrhizus isolate synergic (∑FICI = 0.375) and other isolates in addition (0.5 < ∑FICI < 4).
Conclusions: Doxycycline was found to have in vitro advantages in combined antifungal treatment over antifungals alone.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689593 | PMC |
| http://dx.doi.org/10.1007/s42770-023-01167-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!